Novartis Korea was nominated as a full member nation for ICRO

Published: 2006-12-29 06:57:00

Updated: 2006-12-29 06:57:00

Novartis head office has nominated Novartis Korea as a full member unit for the ICRO (International Clinical Research Operations) of Novartis and decided to expand R&D investment for clinical research works of anti-cancer drugs.

The nomination implied a recognition of Novarti Korea as an affil...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK